+Follow
SaraJT
No personal profile
13
Follow
0
Followers
0
Topic
0
Badge
Posts
Hot
SaraJT
2021-03-17
????
Sorry, the original content has been removed
SaraJT
2021-03-17
??
3 Cancer Diagnostic Stocks To Watch Following Roche's GenMark Buy
SaraJT
2021-03-17
Good earnings
Go to Tiger App to see more news
{"i18n":{"language":"en_US"},"userPageInfo":{"id":"3572604411300346","uuid":"3572604411300346","gmtCreate":1609512365606,"gmtModify":1609512365606,"name":"SaraJT","pinyin":"sarajt","introduction":"","introductionEn":null,"signature":"","avatar":"https://static.laohu8.com/default-avatar.jpg","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":0,"headSize":13,"tweetSize":3,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":1,"name":"萌萌虎","nameTw":"萌萌虎","represent":"呱呱坠地","factor":"评论帖子3次或发布1条主帖（非转发）","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":"success","userBadges":[{"badgeId":"7a9f168ff73447fe856ed6c938b61789-1","templateUuid":"7a9f168ff73447fe856ed6c938b61789","name":"Knowledgeable Investor","description":"Traded more than 10 stocks","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102},{"badgeId":"a83d7582f45846ffbccbce770ce65d84-1","templateUuid":"a83d7582f45846ffbccbce770ce65d84","name":"Real Trader","description":"Completed a transaction","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},{"badgeId":"972123088c9646f7b6091ae0662215be-1","templateUuid":"972123088c9646f7b6091ae0662215be","name":"Elite Trader","description":"Total number of securities or futures transactions reached 30","bigImgUrl":"https://static.tigerbbs.com/ab0f87127c854ce3191a752d57b46edc","smallImgUrl":"https://static.tigerbbs.com/c9835ce48b8c8743566d344ac7a7ba8c","grayImgUrl":"https://static.tigerbbs.com/76754b53ce7a90019f132c1d2fbc698f","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":"60.12%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":3,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":1,"crmLevelSwitch":0,"location":null,"starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"post","tweets":[{"id":324052422,"gmtCreate":1615946015666,"gmtModify":1704788770640,"author":{"id":"3572604411300346","authorId":"3572604411300346","name":"SaraJT","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3572604411300346","authorIdStr":"3572604411300346"},"themes":[],"htmlText":"????","listText":"????","text":"????","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/324052422","repostId":"2119597686","repostType":4,"isVote":1,"tweetType":1,"viewCount":1150,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":324052654,"gmtCreate":1615945991678,"gmtModify":1704788770478,"author":{"id":"3572604411300346","authorId":"3572604411300346","name":"SaraJT","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3572604411300346","authorIdStr":"3572604411300346"},"themes":[],"htmlText":"??","listText":"??","text":"??","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/324052654","repostId":"1178891078","repostType":4,"repost":{"id":"1178891078","kind":"news","pubTimestamp":1615909549,"share":"https://ttm.financial/m/news/1178891078?lang=en_US&edition=fundamental","pubTime":"2021-03-16 23:45","market":"us","language":"en","title":"3 Cancer Diagnostic Stocks To Watch Following Roche's GenMark Buy","url":"https://stock-news.laohu8.com/highlight/detail?id=1178891078","media":"Benzinga","summary":"Roche Holding AGRHHBY 0.17%acquiredGenMark Diagnostics, Inc(NASDAQ: GNMK) in a$1.8 billion deal on M","content":"<div>\n<p>Roche Holding AGRHHBY 0.17%acquiredGenMark Diagnostics, Inc(NASDAQ: GNMK) in a$1.8 billion deal on Monday, the same day Veracyte Inc VCYT 1.76%announcedit completed the acquisition ofDecipher ...</p>\n\n<a href=\"https://www.benzinga.com/general/biotech/21/03/20187640/3-cancer-diagnostic-stocks-to-watch-following-roches-genmark-buy\">Source Link</a>\n\n</div>\n","source":"lsy1606299360108","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Cancer Diagnostic Stocks To Watch Following Roche's GenMark Buy</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Cancer Diagnostic Stocks To Watch Following Roche's GenMark Buy\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-03-16 23:45 GMT+8 <a href=https://www.benzinga.com/general/biotech/21/03/20187640/3-cancer-diagnostic-stocks-to-watch-following-roches-genmark-buy><strong>Benzinga</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Roche Holding AGRHHBY 0.17%acquiredGenMark Diagnostics, Inc(NASDAQ: GNMK) in a$1.8 billion deal on Monday, the same day Veracyte Inc VCYT 1.76%announcedit completed the acquisition ofDecipher ...</p>\n\n<a href=\"https://www.benzinga.com/general/biotech/21/03/20187640/3-cancer-diagnostic-stocks-to-watch-following-roches-genmark-buy\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"source_url":"https://www.benzinga.com/general/biotech/21/03/20187640/3-cancer-diagnostic-stocks-to-watch-following-roches-genmark-buy","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1178891078","content_text":"Roche Holding AGRHHBY 0.17%acquiredGenMark Diagnostics, Inc(NASDAQ: GNMK) in a$1.8 billion deal on Monday, the same day Veracyte Inc VCYT 1.76%announcedit completed the acquisition ofDecipher Biosciences, Inc.\nWhat Happened:With thecancer diagnostic marketexpected to grow to $261.34 billion by 2027 — more than double the $115.60 billion it was worth last year — big biotech companies have been on an acquisition spree to boost their portfolios and technology.\nIn January, Exact Sciences Corporation EXAS 3.64%announcedit completed its acquisition ofThrive Earlier Detection Corp.and got Thrive’s blood-based multi-cancer detection technology.\nWhy It Matters:Early detection of cancer greatly increases the survival rate and smaller biotech companies are showing leadership skills in developing the necessary technology.\nSmaller companies develop specific technology for specific types of cancer which allows them to focus on creating tailored products that are also attractive for larger companies to acquire.\nThe following three companies have developed technology that could make them sought-after acquisition targets:\nBioMark Diagnostics IncBMKDF 13.17%, a biotech company headquartered in Vancouver, British Columbia, has developed a state-of-the-art liquid biopsy technology platform for the early detection of cancer. The unique technologyfinds metabolomicsbiomarkers of hard-to-detect cancers of the lung, brain, ovarian and pancreas.\nBioMark is pivoting into commercialization after many years in the research and development phase. On Feb. 16, the company announced it will collaborate with Phytronix Technologies Inc “to advance the development of BioMark’s early lung cancer screening applications using Phytronix-proprietary Laser Diode Thermal Desorption (LDTD) technology,” BioMark said in a press release.\nThe collaboration will also support BioMark in setting up clinical lab services in Quebec. BioMark plans to demonstrate its technology later in 2021.\nBioMark’s market cap is $28.67 million and its shares are at 41 cents, up 13.17% on Tuesday morning.\nBiocept IncBIOC 0.17%is another company focusing on early cancer detection through blood-based liquid biopsy. The San Diego-based company has two platforms, CTC and ctDNA, used to detect and analyze a patient’s blood for cancer cells and mutations.\nBiocept boasts22 patentsfor its liquid-biopsy technology in the U.S., EU, Australia, China, Japan and South Korea.\nOn Feb. 16, Bioceptannounced its product, Target Selector, is ultra-sensitive and capable of detecting mutations using biopsy specimens usually be deemed “quantity not sufficient.”\nIn a pivot brought on by the pandemic, Biocept alsoannounced on Feb. 3 its lab had processed 250 000 COVID-19 tests using its RT-PCR technology.\nBiocept has a market cap of $79.98 million and the company's shares are at $5.87, down 1.68% Tuesday morning.\nHTG Molecular Diagnostics IncHTGM 3.29%, an Arizona-based biotech company, developed the EdgeSeq Oncology Biomarker Panel to detect colon, breast, prostate and lung cancer from tumor tissue. The analysis tool can detect2,549 genesassociated with tumor biology and results are available only 36 hours following the biopsy collection.\nUnlike BioMark and Biocept, HTG Molecular uses Formalin-Fixed Paraffin-Embedded (FFPE) tissue specimens to test for cancers.\nOn Feb. 26, HTG Molecularannouncedits EdgeSeq technology “demonstrated the ability to generate unique gene expression profiles for multiple cancer indications” and the amount of tissue required in the samples was 4 to 8 times less than required for similar tests.\nHTG Molecular has a market cap of $28.82 million and its shares area t $6.17, up 1.48% on Tuesday morning.","news_type":1,"symbols_score_info":{}},"isVote":1,"tweetType":1,"viewCount":1272,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":324058492,"gmtCreate":1615945863816,"gmtModify":1704788768054,"author":{"id":"3572604411300346","authorId":"3572604411300346","name":"SaraJT","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3572604411300346","authorIdStr":"3572604411300346"},"themes":[],"htmlText":"Good earnings","listText":"Good earnings","text":"Good earnings","images":[{"img":"https://static.tigerbbs.com/98571ea8b13753826de7259149dcac1d","width":"1125","height":"3707"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/324058492","isVote":1,"tweetType":1,"viewCount":1541,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0}],"hots":[{"id":324052422,"gmtCreate":1615946015666,"gmtModify":1704788770640,"author":{"id":"3572604411300346","authorId":"3572604411300346","name":"SaraJT","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3572604411300346","authorIdStr":"3572604411300346"},"themes":[],"htmlText":"????","listText":"????","text":"????","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/324052422","repostId":"2119597686","repostType":4,"isVote":1,"tweetType":1,"viewCount":1150,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":324052654,"gmtCreate":1615945991678,"gmtModify":1704788770478,"author":{"id":"3572604411300346","authorId":"3572604411300346","name":"SaraJT","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3572604411300346","authorIdStr":"3572604411300346"},"themes":[],"htmlText":"??","listText":"??","text":"??","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/324052654","repostId":"1178891078","repostType":4,"repost":{"id":"1178891078","kind":"news","pubTimestamp":1615909549,"share":"https://ttm.financial/m/news/1178891078?lang=en_US&edition=fundamental","pubTime":"2021-03-16 23:45","market":"us","language":"en","title":"3 Cancer Diagnostic Stocks To Watch Following Roche's GenMark Buy","url":"https://stock-news.laohu8.com/highlight/detail?id=1178891078","media":"Benzinga","summary":"Roche Holding AGRHHBY 0.17%acquiredGenMark Diagnostics, Inc(NASDAQ: GNMK) in a$1.8 billion deal on M","content":"<div>\n<p>Roche Holding AGRHHBY 0.17%acquiredGenMark Diagnostics, Inc(NASDAQ: GNMK) in a$1.8 billion deal on Monday, the same day Veracyte Inc VCYT 1.76%announcedit completed the acquisition ofDecipher ...</p>\n\n<a href=\"https://www.benzinga.com/general/biotech/21/03/20187640/3-cancer-diagnostic-stocks-to-watch-following-roches-genmark-buy\">Source Link</a>\n\n</div>\n","source":"lsy1606299360108","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Cancer Diagnostic Stocks To Watch Following Roche's GenMark Buy</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Cancer Diagnostic Stocks To Watch Following Roche's GenMark Buy\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-03-16 23:45 GMT+8 <a href=https://www.benzinga.com/general/biotech/21/03/20187640/3-cancer-diagnostic-stocks-to-watch-following-roches-genmark-buy><strong>Benzinga</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Roche Holding AGRHHBY 0.17%acquiredGenMark Diagnostics, Inc(NASDAQ: GNMK) in a$1.8 billion deal on Monday, the same day Veracyte Inc VCYT 1.76%announcedit completed the acquisition ofDecipher ...</p>\n\n<a href=\"https://www.benzinga.com/general/biotech/21/03/20187640/3-cancer-diagnostic-stocks-to-watch-following-roches-genmark-buy\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"source_url":"https://www.benzinga.com/general/biotech/21/03/20187640/3-cancer-diagnostic-stocks-to-watch-following-roches-genmark-buy","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1178891078","content_text":"Roche Holding AGRHHBY 0.17%acquiredGenMark Diagnostics, Inc(NASDAQ: GNMK) in a$1.8 billion deal on Monday, the same day Veracyte Inc VCYT 1.76%announcedit completed the acquisition ofDecipher Biosciences, Inc.\nWhat Happened:With thecancer diagnostic marketexpected to grow to $261.34 billion by 2027 — more than double the $115.60 billion it was worth last year — big biotech companies have been on an acquisition spree to boost their portfolios and technology.\nIn January, Exact Sciences Corporation EXAS 3.64%announcedit completed its acquisition ofThrive Earlier Detection Corp.and got Thrive’s blood-based multi-cancer detection technology.\nWhy It Matters:Early detection of cancer greatly increases the survival rate and smaller biotech companies are showing leadership skills in developing the necessary technology.\nSmaller companies develop specific technology for specific types of cancer which allows them to focus on creating tailored products that are also attractive for larger companies to acquire.\nThe following three companies have developed technology that could make them sought-after acquisition targets:\nBioMark Diagnostics IncBMKDF 13.17%, a biotech company headquartered in Vancouver, British Columbia, has developed a state-of-the-art liquid biopsy technology platform for the early detection of cancer. The unique technologyfinds metabolomicsbiomarkers of hard-to-detect cancers of the lung, brain, ovarian and pancreas.\nBioMark is pivoting into commercialization after many years in the research and development phase. On Feb. 16, the company announced it will collaborate with Phytronix Technologies Inc “to advance the development of BioMark’s early lung cancer screening applications using Phytronix-proprietary Laser Diode Thermal Desorption (LDTD) technology,” BioMark said in a press release.\nThe collaboration will also support BioMark in setting up clinical lab services in Quebec. BioMark plans to demonstrate its technology later in 2021.\nBioMark’s market cap is $28.67 million and its shares are at 41 cents, up 13.17% on Tuesday morning.\nBiocept IncBIOC 0.17%is another company focusing on early cancer detection through blood-based liquid biopsy. The San Diego-based company has two platforms, CTC and ctDNA, used to detect and analyze a patient’s blood for cancer cells and mutations.\nBiocept boasts22 patentsfor its liquid-biopsy technology in the U.S., EU, Australia, China, Japan and South Korea.\nOn Feb. 16, Bioceptannounced its product, Target Selector, is ultra-sensitive and capable of detecting mutations using biopsy specimens usually be deemed “quantity not sufficient.”\nIn a pivot brought on by the pandemic, Biocept alsoannounced on Feb. 3 its lab had processed 250 000 COVID-19 tests using its RT-PCR technology.\nBiocept has a market cap of $79.98 million and the company's shares are at $5.87, down 1.68% Tuesday morning.\nHTG Molecular Diagnostics IncHTGM 3.29%, an Arizona-based biotech company, developed the EdgeSeq Oncology Biomarker Panel to detect colon, breast, prostate and lung cancer from tumor tissue. The analysis tool can detect2,549 genesassociated with tumor biology and results are available only 36 hours following the biopsy collection.\nUnlike BioMark and Biocept, HTG Molecular uses Formalin-Fixed Paraffin-Embedded (FFPE) tissue specimens to test for cancers.\nOn Feb. 26, HTG Molecularannouncedits EdgeSeq technology “demonstrated the ability to generate unique gene expression profiles for multiple cancer indications” and the amount of tissue required in the samples was 4 to 8 times less than required for similar tests.\nHTG Molecular has a market cap of $28.82 million and its shares area t $6.17, up 1.48% on Tuesday morning.","news_type":1,"symbols_score_info":{}},"isVote":1,"tweetType":1,"viewCount":1272,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":324058492,"gmtCreate":1615945863816,"gmtModify":1704788768054,"author":{"id":"3572604411300346","authorId":"3572604411300346","name":"SaraJT","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3572604411300346","authorIdStr":"3572604411300346"},"themes":[],"htmlText":"Good earnings","listText":"Good earnings","text":"Good earnings","images":[{"img":"https://static.tigerbbs.com/98571ea8b13753826de7259149dcac1d","width":"1125","height":"3707"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/324058492","isVote":1,"tweetType":1,"viewCount":1541,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0}],"lives":[]}
